Qilian International Holding Group (BGM) Competitors $10.12 +0.23 (+2.27%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$9.99 -0.13 (-1.28%) As of 02/21/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends BGM vs. GOSS, CADL, ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, and TVGNShould you be buying Qilian International Holding Group stock or one of its competitors? The main competitors of Qilian International Holding Group include Gossamer Bio (GOSS), Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry. Qilian International Holding Group vs. Gossamer Bio Candel Therapeutics Atyr PHARMA Immutep Olema Pharmaceuticals Korro Bio Neumora Therapeutics Y-mAbs Therapeutics Kodiak Sciences Tevogen Bio Qilian International Holding Group (NASDAQ:BGM) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Which has better earnings & valuation, BGM or GOSS? Qilian International Holding Group has higher revenue and earnings than Gossamer Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQilian International Holding Group$25.10M2.42-$1.44MN/AN/AGossamer BioN/AN/A-$179.82M-$0.32-4.38 Do analysts prefer BGM or GOSS? Gossamer Bio has a consensus target price of $9.20, suggesting a potential upside of 557.14%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BGM or GOSS more profitable? Qilian International Holding Group's return on equity of 0.00% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Qilian International Holding GroupN/A N/A N/A Gossamer Bio N/A -127.28%-22.12% Does the media favor BGM or GOSS? In the previous week, Qilian International Holding Group and Qilian International Holding Group both had 1 articles in the media. Qilian International Holding Group's average media sentiment score of 0.00 equaled Gossamer Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qilian International Holding Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer BGM or GOSS? Gossamer Bio received 152 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformQilian International Holding GroupN/AN/AGossamer BioOutperform Votes15266.38% Underperform Votes7733.62% Do institutionals & insiders have more ownership in BGM or GOSS? 81.2% of Gossamer Bio shares are owned by institutional investors. 58.7% of Qilian International Holding Group shares are owned by insiders. Comparatively, 5.0% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, BGM or GOSS? Qilian International Holding Group has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. SummaryGossamer Bio beats Qilian International Holding Group on 6 of the 11 factors compared between the two stocks. Get Qilian International Holding Group News Delivered to You Automatically Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGM vs. The Competition Export to ExcelMetricQilian International Holding GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.46M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.7326.0419.11Price / Sales2.42306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book1.666.717.644.62Net Income-$1.44M$138.33M$3.18B$245.85M7 Day Performance-1.51%-2.63%-2.00%-2.61%1 Month Performance-5.37%-2.33%-0.44%-2.14%1 Year PerformanceN/A-5.33%16.44%12.98% Qilian International Holding Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGMQilian International Holding GroupN/A$10.13+2.3%N/AN/A$59.46M$25.10M0.00298High Trading VolumeGOSSGossamer Bio3.9678 of 5 stars$1.31flat$9.20+602.3%+14.8%$296.85MN/A-4.09180Positive NewsHigh Trading VolumeCADLCandel Therapeutics3.5699 of 5 stars$9.05+2.6%$17.00+87.8%+560.8%$293.91M$120,000.00-5.2360Analyst ForecastNews CoverageATYRAtyr PHARMA2.8123 of 5 stars$3.41-5.0%$19.25+464.5%N/A$286.24M$350,000.00-3.6353Analyst ForecastAnalyst RevisionNews CoverageGap UpIMMPImmutep0.9684 of 5 stars$1.96+0.5%$8.50+333.7%-13.9%$285.30M$5.14M0.002,021Upcoming EarningsOLMAOlema Pharmaceuticals3.2688 of 5 stars$4.97+2.9%$28.75+478.5%-64.0%$284.78MN/A-2.2770KRROKorro Bio0.9143 of 5 stars$30.02+3.2%$144.00+379.7%-51.4%$281.29MN/A0.0070News CoverageGap UpNMRANeumora Therapeutics4.074 of 5 stars$1.74+3.0%$16.50+848.3%-90.0%$281.11MN/A-0.93108News CoverageYMABY-mAbs Therapeutics2.5862 of 5 stars$6.24+1.1%$20.89+234.8%-65.3%$279.49M$84.82M-11.56150News CoverageKODKodiak Sciences4.253 of 5 stars$5.26+3.1%$8.00+52.1%-14.6%$276.78MN/A-1.4490Positive NewsTVGNTevogen Bio3.4266 of 5 stars$1.58+1.3%$4.20+165.8%-82.1%$276.58MN/A0.003 Related Companies and Tools Related Companies GOSS Competitors CADL Competitors ATYR Competitors IMMP Competitors OLMA Competitors KRRO Competitors NMRA Competitors YMAB Competitors KOD Competitors TVGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BGM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qilian International Holding Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Qilian International Holding Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
